345 related articles for article (PubMed ID: 26632930)
1. Adalimumab-induced psoriatic alopecia/alopecia areata-like reaction in a patient with Crohn's disease.
Toda-Brito H; Lopes L; Soares-Almeida L; Filipe P
Dermatol Online J; 2015 Nov; 21(11):. PubMed ID: 26632930
[TBL] [Abstract][Full Text] [Related]
2. Alopecia areata following adalimumab.
Kirshen C; Kanigsberg N
J Cutan Med Surg; 2009; 13(1):48-50. PubMed ID: 19298772
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab-related alopecia in a patient affected by psoriasis.
Melé-Ninot G; Expósito-Serrano V; Quintana Codina M; Iglesias Sancho M; Sánchez-Regaña M; Umbert Millet P; Salleras Redonnet M
Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469696
[TBL] [Abstract][Full Text] [Related]
4. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
[TBL] [Abstract][Full Text] [Related]
5. Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-α therapy: a novel cause of noncicatricial alopecia.
Doyle LA; Sperling LC; Baksh S; Lackey J; Thomas B; Vleugels RA; Qureshi AA; Velazquez EF
Am J Dermatopathol; 2011 Apr; 33(2):161-6. PubMed ID: 21317611
[TBL] [Abstract][Full Text] [Related]
6. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
[TBL] [Abstract][Full Text] [Related]
7. Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies.
Barthel C; Biedermann L; Frei P; Vavricka SR; Kündig T; Fried M; Rogler G; Scharl M
Digestion; 2014; 89(3):209-15. PubMed ID: 24853251
[TBL] [Abstract][Full Text] [Related]
8. Alopecia areata during treatment with adalimumab: therapy with an alternative TNF-alpha inhibitor is possible.
Zschoche C; Bidier M; Hadaschik E
J Dtsch Dermatol Ges; 2013 May; 11(5):450-3. PubMed ID: 23279686
[No Abstract] [Full Text] [Related]
9. Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab.
Andrisani G; Marzo M; Celleno L; Guidi L; Papa A; Gasbarrini A; Armuzzi A
Eur Rev Med Pharmacol Sci; 2013 Oct; 17(20):2831-6. PubMed ID: 24174369
[TBL] [Abstract][Full Text] [Related]
10. Alopecia areata universalis elicited during treatment with adalimumab.
Pelivani N; Hassan AS; Braathen LR; Hunger RE; Yawalkar N
Dermatology; 2008; 216(4):320-3. PubMed ID: 18230980
[TBL] [Abstract][Full Text] [Related]
11. Alopecia areata induced by Adalimumab in a patient with Crohn's disease.
Esposito G; Spennato S; Guerriero L; Ruggiero F; Patrì A; Fabbrocini G; Nastro F
Dermatol Ther; 2022 Dec; 35(12):e15940. PubMed ID: 36251322
[No Abstract] [Full Text] [Related]
12. [Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease].
Avila Alvarez A; García-Alonso L; Solar Boga A; García-Silva J
An Pediatr (Barc); 2009 Mar; 70(3):278-81. PubMed ID: 19409245
[TBL] [Abstract][Full Text] [Related]
13. First case report of adalimumab-induced psoriasis in Crohn's disease.
Harris MD; Richards R
Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532
[No Abstract] [Full Text] [Related]
14. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.
Peer FC; Miller A; Pavli P; Subramaniam K
Intern Med J; 2017 Dec; 47(12):1445-1448. PubMed ID: 29224199
[TBL] [Abstract][Full Text] [Related]
15. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities.
Piérard GE; Piérard-Franchimont C; Szepetiuk G; Paquet P; Quatresooz P
Expert Opin Biol Ther; 2010 Aug; 10(8):1197-208. PubMed ID: 20560729
[TBL] [Abstract][Full Text] [Related]
17. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
18. Persistent neutrophilic scarring alopecia triggered by anti-TNF blockade for Crohn's disease.
Amschler K; Mc Broekaert S; Mohr J; Schön MP; Mößner R
Eur J Dermatol; 2018 Jun; 28(3):403-405. PubMed ID: 29976546
[No Abstract] [Full Text] [Related]
19. TNF inhibitor induced alopecia: an unusual form of psoriasiform alopecia that breaks the Renbök mold.
Craddock LN; Cooley DM; Endo JO; Longley BJ; Caldera F
Dermatol Online J; 2017 Mar; 23(3):. PubMed ID: 28329519
[TBL] [Abstract][Full Text] [Related]
20. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.
George LA; Gadani A; Cross RK; Jambaulikar G; Ghazi LJ
Dig Dis Sci; 2015 Nov; 60(11):3424-30. PubMed ID: 26115749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
